Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;39(12):2778-2786.
doi: 10.1111/jgh.16771. Epub 2024 Oct 16.

Cost-effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients

Hui-Min Hsieh  1   2   3   4   5 , Chi-Mei Ho  1 , Yi-Hsun Chen  6   7 , Wen-Hung Hsu  6   8 , Yao-Kuang Wang  6   8 , Yen-Yun Wang  2   9 , Shyng-Shiou F Yuan  2   10   11   12 , I-Chen Wu  6   8   13
Affiliations

Cost-effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients

Hui-Min Hsieh et al. J Gastroenterol Hepatol. 2024 Dec.

Abstract

Background and aim: Oral and esophageal cancers are globally prevalent, especially in East Asia. Over half of head and neck cancer patients developing second primary esophageal cancer (SPEC) were initially diagnosed with oral cavity cancer (OCC). This study assessed the cost-effectiveness of universal endoscopic screening for early SPEC prevention in newly diagnosed OCC patients at different stages.

Methods: This study employed Markov cohort models to evaluate the cost-effectiveness of endoscopic SPEC screening post-OCC diagnosis (stages 0 to IV) between screened and non-screened groups. Four surveillance frequencies were assessed: (i) one time, (ii) annual for 3 years, (iii) annual for 10 years, and (iv) annual for life. A hypothetical cohort of 100 000 cases across stages was compared for costs and quality-adjusted life-years (QALYs), discounted annually at 3%.

Results: All four screening strategies were beneficial for all OCC stages, especially for early-stage patients, resulting in higher QALYs. Lifetime/annual screening from the payer's perspective proved most favorable, with incremental QALYs of 1.23 at stage 0 and 0.06 at stage IV. Incremental costs for this strategy ranged from NTD 121 331 (USD 4044) at stage 0 to NTD 13 032 (USD 434) at stage IV. Both incremental costs and incremental cost-effectiveness ratio (ICER) values indicated cost savings from a societal perspective. The ICER values ranged from NTD -626 440 (USD -20 881) at stage 0 and NTD -475 021 (USD -15 834) at stage IV.

Conclusions: Overall, our study provided cost-effectiveness evidences to understanding the cost-effectiveness of endoscopic screening in OCC patients, particularly emphasizing the benefits of early and consistent screening.

Keywords: Cost‐effectiveness analysis; Endoscopic screening; Oral cavity cancer; Second primary esophageal cancer.

PubMed Disclaimer

References

REFERENCES

    1. Nocini R, Lippi G, Mattiuzzi C. Biological and epidemiologic updates on lip and oral cavity cancers. Annal. Cancer Epidemiol. 2020; 4: 1–6.
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021. https://doi.org/10.3322/caac.21660.
    1. Liu CQ, Ma YL, Qin Q, Wang PH, Luo Y, Xu PF, Cui Y. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 2023; 14: 3–11. https://doi.org/10.1111/1759‐7714.14745.
    1. Huang SY, Chen HM, Liao KH, Ko BS, Hsiao FY. Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017. BMJ Open 2020; 10: e036341. https://doi.org/10.1136/bmjopen‐2019‐036341.
    1. Lee K‐D, Wang T‐Y, Lu C‐H, Huang C‐E, Chen M‐C. The bidirectional association between oral cancer and esophageal cancer: a population‐based study in Taiwan over a 28‐year period. Oncotarget 2017; 8: 44567–44578.

MeSH terms

LinkOut - more resources